BioMarin Pharmaceutical Inc. announced that based on recent meetings with health authorities in the US and Europe, the Company plans to submit marketing applications to the FDA and… read more.
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations The Company announced measures it… read more.
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs , drug supply chain, and business operations. The Company announced measures… read more.
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs , drug supply chain, and business operations. The Company announced measures… read more.
A case study of a patient in Wuhan, China, suggests that the immunosuppressant Actemra (tocilizumab) from Roche may be an effective COVID-19 treatment for very ill patients who… read more.
Bristol Myers Squibb and Acceleron Pharma Inc. announced the FDA has approved Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing… read more.
-BD (Becton, Dickinson and Company) , a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the FDA has granted Emergency Use Authorization… read more.
Vanda Pharmaceuticals Inc. announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation… read more.
Novan, Inc. announced that the Company has conducted its Type C meeting with the FDA regarding SB 206 for the treatment of molluscum. The purpose of the meeting… read more.
GlaxoSmithKline announced positive results from the pivotal phase III SYNAPSE study of Nucala (mepolizumab) in patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This is the first… read more.
-BD (Becton, Dickinson and Company) , a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the FDA has granted Emergency Use Authorization… read more.
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
